84 related articles for article (PubMed ID: 9816048)
1. Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Figg WD; Cole KA; Reed E; Steinberg SM; Piscitelli SC; Davis PA; Soltis MJ; Jacob J; Boudoulas S; Goldspiel B
Clin Cancer Res; 1995 Aug; 1(8):797-803. PubMed ID: 9816048
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA
Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
Berlin J; Tutsch KD; Arzoomanian RZ; Alberti D; Binger K; Feierabend C; Dresen A; Marnocha R; Pluda J; Wilding G
Clin Cancer Res; 2002 Jan; 8(1):86-94. PubMed ID: 11801543
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Berlin J; Tutsch KD; Hutson P; Cleary J; Rago RP; Arzoomanian RZ; Alberti D; Feierabend C; Wilding G
J Clin Oncol; 1997 Feb; 15(2):781-9. PubMed ID: 9053505
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Bauer KS; Figg WD; Hamilton JM; Jones EC; Premkumar A; Steinberg SM; Dyer V; Linehan WM; Pluda JM; Reed E
Clin Cancer Res; 1999 Sep; 5(9):2324-9. PubMed ID: 10499600
[TBL] [Abstract][Full Text] [Related]
15. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
